David Rider

David Rider has a diverse work experience spanning multiple companies and roles. David began their career as a Postdoctoral Fellow at The Babraham Institute, where they conducted research on the effects of therapeutic antibodies on T cell lymphoma. David then moved on to A*STAR, where they worked as a Postdoctoral Research Fellow focusing on stem cell differentiation and expansion. In 2008, David joined MedImmune as a Scientist I, specializing in respiratory, inflammation, and autoimmunity biology. David later joined the Grünenthal Group, where they held various positions including Senior Scientific Manager and Team Leader, contributing to research in inflammation and leading international projects. Currently, David is working at Silence Therapeutics plc as the Head of Pre-Clinical Development and has recently transitioned into the role of Project Director.

David Rider earned a Bachelor of Science (BSc) degree in Biochemistry and Genetics from The University of Sheffield, where they studied from 1995 to 1998. David then pursued a Master of Science (MSc) degree in Immunology at the University of Birmingham from 1998 to 1999. Following this, David continued their education at the University of Birmingham, obtaining a Doctor of Philosophy (PhD) degree in Immunology, which they completed between 1999 and 2003. In addition to their academic achievements, David Rider also obtained a Project Management Professional (PMP) certification from the Project Management Institute in October 2022. Regarding EPS 2015, no specific information regarding the degree, field of study, or dates is available.